What are the recommended management strategies for an older adult with suspected cerebral amyloid angiopathy presenting with lobar intracerebral hemorrhage, cortical superficial siderosis, or progressive cognitive decline?

Management of Cerebral Amyloid Angiopathy

For older adults with suspected cerebral amyloid angiopathy presenting with lobar intracerebral hemorrhage, cortical superficial siderosis, or progressive cognitive decline, immediately discontinue all anticoagulants and antiplatelets, obtain brain MRI with specific sequences (T2 FLAIR, DWI, T2 GRE or SWI) to establish diagnosis using modified Boston criteria, strictly control blood pressure, and avoid restarting anticoagulation especially in lobar hemorrhage cases due to high recurrence risk.* 1, 2, 3

Diagnostic Approach

Imaging Requirements

• Brain MRI without contrast is the primary diagnostic modality, requiring T2 FLAIR, diffusion-weighted imaging (DWI), and T2* gradient-echo (GRE) or susceptibility-weighted imaging (SWI) sequences 1, 3, 4
• 3T MRI provides superior sensitivity compared to 1.5T for detecting microhemorrhages and other CAA markers 5, 4
• CT head without contrast is acceptable when MRI is contraindicated but has lower sensitivity for detecting cortical superficial siderosis and microbleeds 1

Key Imaging Biomarkers to Identify

• Lobar intracerebral hemorrhages (cortical or cortico-subcortical location, sparing deep structures) 6, 7, 2, 3
• Cortical superficial siderosis (cSS) - hemosiderin deposition appearing as linear hypointensity along cortical surface, particularly disseminated cSS which predicts higher ICH recurrence risk 1, 6, 8, 9
• Lobar cerebral microbleeds on T2* GRE or SWI sequences 1, 6, 10, 3
• White matter hyperintensities on T2 FLAIR 6, 7, 10
• Dilated centrum semiovale perivascular spaces 8, 10
• Cortical microinfarcts and lobar lacunes 8, 10

Diagnostic Criteria Application

• Apply modified Boston criteria version 2.0 which incorporate clinical presentation plus MRI findings to establish probable or possible CAA without requiring pathological confirmation 6, 7, 10, 3
• Definite CAA requires neuropathological examination showing vascular amyloid-β deposition, which is rarely pursued given invasiveness 6, 3, 4

Acute Management of Intracerebral Hemorrhage

Immediate Antithrombotic Management

• Discontinue all anticoagulants and antiplatelet agents immediately for at least 1-2 weeks during the acute hemorrhage period 1
• Reverse warfarin effect immediately using fresh frozen plasma or prothrombin complex concentrate plus vitamin K 1
• Use protamine sulfate to reverse heparin-associated ICH, with dosing dependent on time from heparin cessation 1
• Failure to achieve normal INR is associated with increased rebleeding risk 1

Blood Pressure Control

• Implement strict blood pressure control as the primary modifiable risk factor for preventing hemorrhage recurrence 1, 10, 3
• Target blood pressure goals should be aggressive given the high recurrence risk in CAA 2, 10

Long-Term Antithrombotic Decision-Making

Anticoagulation Considerations

• Avoid restarting anticoagulation in patients with lobar ICH and CAA, particularly in elderly patients where underlying cerebral amyloid angiopathy is likely 1
• A decision analysis study specifically recommended against restarting anticoagulation in patients with lobar ICH and atrial fibrillation due to high recurrence risk 1
• For patients with very high thromboembolism risk (prosthetic heart valves), if anticoagulation restart is considered, wait at least 7-10 days after ICH onset, though this carries substantial hemorrhage risk 1

Risk Stratification for Recurrent Hemorrhage

The following factors indicate higher bleeding risk and should weigh heavily against anticoagulation 1, 3:

• Lobar location of initial ICH (versus deep location) 1
• Presence and number of lobar microbleeds on MRI 1, 3
• Disseminated cortical superficial siderosis on MRI 1, 3
• Advanced age 1, 3
• Poorly controlled hypertension 1
• APOE ε2 or ε4 alleles (particularly ε2/ε2 homozygotes who show aggressive hemorrhagic progression) 1, 9

Antiplatelet Agent Decisions

• For patients with comparatively lower thromboembolism risk (e.g., atrial fibrillation without prior ischemic stroke) and higher CAA bleeding risk (elderly with lobar ICH), an antiplatelet agent may be considered as a compromise, though this still carries hemorrhage risk 1
• The risk/benefit evaluation of antiplatelet agents requires individual assessment given ongoing bleeding risk 10

Alternative Strategies for Atrial Fibrillation

• Consider nonpharmacological alternatives such as left atrial appendage closure in patients with concurrent atrial fibrillation who have CAA, avoiding lifelong anticoagulation 2, 3

Management of Cognitive Decline

Cognitive Assessment and Monitoring

• CAA causes cognitive impairment across multiple domains, with particularly high risk of developing dementia after ICH 1, 8
• Screen for cognitive decline using standardized measures, as subjective complaints are common but influenced by depression and psychological distress 1
• Lobar hemorrhages associated with CAA carry greater cognitive risk than deep hemorrhages 1

Pharmacological Treatment of Dementia

• Consider cholinesterase inhibitors (donepezil) for mild to moderate dementia after ICH, as they improve cognitive function and activities of daily living in vascular cognitive impairment 1
• Consider memantine for moderate to severe dementia after ICH, as it shows beneficial effects on cognitive function, activities of daily living, and mood 1
• Common side effects: donepezil causes nausea, diarrhea, anorexia, and cramps; memantine causes headaches and dizziness 1

Depression Management

• Reserve SSRIs for moderate to severe depression only in CAA patients, as meta-analyses show small but increased ICH risk with SSRIs, especially when combined with anticoagulation 1
• This increased hemorrhage risk can translate to worsened 3-month neurological outcomes 1
• Balance the importance of treating depression against hemorrhage risk by limiting SSRIs to cases where depression severity warrants intervention 1

Special Clinical Presentations

Transient Focal Neurological Episodes ("Amyloid Spells")

• Recognize that CAA causes transient focal neurological deficits often misdiagnosed as seizures or transient ischemic attacks in emergency settings 6, 7
• These episodes are attributed to convexity subarachnoid hemorrhage or cortical superficial siderosis 6, 7, 8

Convexity Subarachnoid Hemorrhage

• Cortical SAH (cSAH) represents acute-phase bleeding into subarachnoid space, appearing as single linear hypointensity on MRI, distinct from aneurysmal SAH 7, 9
• cSAH is an important predictor of recurrent ICH and often precedes development of cortical superficial siderosis 1, 8, 9

CAA-Related Inflammation

• A minority of CAA patients develop autoimmune inflammatory reaction (CAA-related inflammation) presenting with rapid cognitive decline and neurological deficits 6, 7, 2
• This inflammatory subtype should be recognized early and treated promptly with immunosuppressive therapy (corticosteroids) to achieve better functional outcomes 6, 2, 3
• MRI may show cerebral edema and white matter changes beyond typical CAA findings 7, 2

Critical Considerations for Anti-Amyloid Immunotherapy

Screening Before Treatment

• Patients being considered for anti-amyloid monoclonal antibodies (lecanemab, donanemab) for Alzheimer's disease must undergo baseline brain MRI to screen for CAA-related contraindications 1, 5, 11
• Exclusionary findings include macrohemorrhages, multiple microhemorrhages, superficial siderosis, vasogenic edema, and significant white matter hyperintensities 1, 5

ARIA Risk in CAA Patients

• CAA patients receiving anti-amyloid therapy face increased risk of amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema) and ARIA-H (hemorrhage) 5, 11, 4
• APOE ε4 carriers, particularly homozygotes, have substantially elevated ARIA risk (33% in ε4/ε4 versus 4.3% in non-carriers) 5, 11
• Mandatory MRI monitoring during treatment is required to detect ARIA development 1, 5, 11

Recurrence Risk and Prognosis

Hemorrhage Recurrence Rates

• CAA-related ICH has recurrence risk of 7.4% per year, substantially higher than non-CAA ICH (1.1% per year) 1
• Risk is highest in the first year after initial hemorrhage 1
• Presence of disseminated cortical superficial siderosis and multiple lobar microbleeds are the strongest predictors of recurrence 1, 3

Overall Vascular Risk

• Patients with CAA remain at risk for both recurrent hemorrhage and ischemic stroke, requiring careful weighing of antithrombotic risks versus benefits 1, 3
• The presence of microbleeds on MRI (particularly multiple lobar microbleeds) signifies underlying microangiopathy and predicts 9.3% ICH risk with anticoagulation versus 1.3% without prior hemorrhage evidence 1

Current Treatment Limitations and Future Directions

• No targeted therapy currently exists to cure or halt CAA progression 6, 2, 10
• Management remains primarily supportive, focused on blood pressure control and avoiding antithrombotics 2, 10, 3
• Various clinical trials are investigating potential disease-modifying therapies targeting amyloid-β deposition 6, 2